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Introduction. The number of new psychoactive substances (NPS) advertised for sale online is constantly increasing and it has
become a phenomenon of global concern. Among NPS, Camfetamine has been rediscovered as recreational drug in 2011. Very
little information is still available in the scientific literature on its nature and potential health risks. Methods. Data in scientific
literaturewere integratedwith amultilingual qualitative assessment of a range of online resources over the period of 32months (May
2011–January 2014). Results. N-Methyl-3-phenyl-norbornan-2-amine (Camfetamine) may act as an indirect dopaminergic agonist
in the central nervous system and may have mild-moderate opioid activity too. There are no current epidemiological data about
recreational use of Camfetamine; our research shows that it is indeed used especially by individuals with a history of recreational
polydrug misuse. It facilitates mental alertness, induces relaxation, and, unlike many other stimulants, seems not to be associated
with severe physical effects. Valid causes for concern issued in our research may be Camfetamine intravenous or intramuscular
administration as well as its use in conjunction with other psychoactive substances. Conclusions. It is here highlighted that more
large-scale studies need to be carried out to confirm and better describe both the extent of Camfetamine misuse and possible
psychotropic/adverse effects.
1. Introduction
The term “new psychoactive substances” (NPS) had been
legally defined earlier by the European Union as a new
narcotic or psychotropic drug, in pure form or in a prepa-
ration, that is, not scheduled under the Single Convention on
Narcotic Drugs of 1961 or the Convention on Psychotropic
Substances of 1971, but which may pose a public health
threat comparable to that posed by substances listed in
those conventions (Council of the European Union decision
2005/387/JHA) [1]. That legal definition is now widely used
and has also been adopted by the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) [2]. The
term “new” does not necessarily refer to newly synthetized
substances but to a wide range of products that have recently
become available on illicit drug market. Many NPS were
indeed synthesized and patented decades ago for research
purposes, but only recently their chemistry or process of
synthesis has been rediscovered or slightly modified to
produce effects similar to known illicit substances [3]. In
this paper, the authors focus on this specific compound
N-methyl-3-phenyl-norbornan-2-amine (Camfetamine), a
stimulant drugwith effects similar to amphetamine. Precisely,
N-methyl-3-phenyl-norbornan-2-amine was developed and
patented as an analeptic by Merck, Darmsradt, in 1961
(Figure 1). Its synthesis was also described by a group in
Smith Kline and French Laboratories when it was pre-
pared as a part of a study to elucidate the stereochemistry
of 3-phenyl-norbornan-2-amine [4]; however, it was never
commercialized. Indeed, the N-ethyl analogue of 3-phenyl-
norbornan-2-amine (Fencamfamine) is better known and
has been sold under the trade name Reactivan as a central
nervous system (CNS) stimulant and appetite suppressant,
also prescribed for reduced performance and for rehabilita-
tion after prolonged and debilitating diseases [5] (Figure 2).
Fencamfamine seems also to have been frequently reported
as dope substance in sport [6]. While Fencamfamine is listed
in the Schedule IV of the UN Convention on Psychotropic
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Substances, Camfetamine is not listed and appears worldwide
mostly unregulated; some exceptions are represented by Por-
tugal, Hungary, and Poland [7–9]. Recently, the Association
of Independent Research Chemical Retailers (AIRCR), an
umbrella organization for a number of online vendors, has
redeveloped it for use as a recreational drug [10]. According
to our onlinemonitoring activity, the first reports about Cam-
fetamine misuse appeared in May 2011 [11]. Concomitantly,
in 2011 Camfetamine was reported among NPS seizures by
official authorities in several countries as United Kingdom,
Finland, and Israel [3, 7, 8]. In 2013, Camfetamine was
identified in mixtures with methoxetamine, caffeine, taurine,
and methiopropamine in Germany [12]. However, very little
information is still available in the scientific literature on
Camfetamine nature and potential health risks related to its
use as a recreational drug.
2. Materials and Methods
The literature on Camfetamine was searched in three
databases: PsycINFO, PubMed, and Medscape. Keywords
used to carry out the database searches included the fol-
lowing: “ N-methyl-3-phenyl-norbornan-2-amine,” “Cam-
fetamine,” and “N-methyl-3-phenylbicyclo[2.2.1]heptan-2-
amine.”
Considering the limitation of peer-reviewed data in sci-
entific literature, results were integrated with a multilingual
qualitative assessment of a range of websites, drug fora, and
other online resources (i.e., e-newsgroups, chat-rooms, mail-
ing lists, e-newsletters, and bulletin boards). This was carried
out using the Google search engine in two languages (English
and Italian). The online assessment was carried out over the
period of 32 months (May 2011–January 2014) and involved
the close monitoring of the sources listed above. Once the
Camfetamine availability of information was identified on
these websites, further specific searches were carried out for
narratives focusing on the following issues: (i) the nature of its
effects on users, including adverse reactions; (ii) motivations
behind its recreational use and possible trends of misuse,
with particular attention to polydrug misuse/idiosyncratic
combinations; (iii) any other relevant information. For the
purpose of reporting the results in this paper, any data
collected from online fora, such as usernames and complete
URLs for specific threads that were considered personal
identifiable, were anonymized. Permission for the study
was granted by the School of Pharmacy Ethics Committee,
University of Hertfordshire, Hatfield, UK (November 2013;
PHAEC/10-42).
3. Results and Discussion
3.1. Pharmacology and Possible Mechanisms of Action of Cam-
fetamine. When considering the myriad structures of syn-
thetic amphetamines and MDMA derivatives it is essential
to return to the structural backbone that is common amongst
them—the 𝛽-phenylethylaminemolecule. Phenylethylamine
(from the Greek root Phainein, meaning to show or to illumi-
nate) is the term used to describe any structure derived from
an aromatic group adjoined to a terminal amine by an ethyl
group (Figure 2). This apparent structural simplicity belies
the vast number of novel psychoactive substances and their
corresponding and varied psychoactive effects that can be
produced from modifications to the phenylethylamine back-
bone [13]. Camfetamine (N-methyl-3-phenylnorbornan-2-
amine) and its N-ethyl analogue Fencamfamine are hete-
rocyclic amphetamine derivatives (Figure 2). Some authors
suggest thatmodifying the aminoalkyl side chain into hetero-
cyclic structures still preserves the basic 𝛽-phenethylamine
structure and retains the central stimulant activity without
marked anorexigenic and cardiovascular side effects [14].
Only two results are currently displayed in scientific
literature on Camfetamine. In the first paper, Kavanagh and
colleagues [10] have described the synthesis of N-methyl-
3-phenyl-norbornan-2-amine (chemical name N-methyl-3-
phenylbicyclo[2.2.1]heptan-2-amine, Camfetamine shown in
Figure 1), its characterization and interpretations of its elec-
tron impact, and electrospray ionization mass spectra. The
authors highlight that the appereance of a new recreational
drug always poses the problem of obtaining an authentic
reference standard for use in forensic analysis [10]. In the
second paper, Welter and colleagues [15] have aimed to
study themetabolic fate and the detectability of Camfetamine
(CAM) in rat urine and to elucidate which cytochrome-
P450 (CYP) isoenzymes are involved in the main metabolic
steps.The following main metabolic pathways were deduced:
N-demethylation, aromatic mono or bis-hydroxylation fol-
lowed by methylation of one hydroxy group, hydroxylation
of the norbornane ring, combination of these steps, and
glucuronidation and/or sulfation of the hydroxy metabo-
lites [15]. The progressive metabolization was catalyzed by
CYP2B6, CYP2C19, CYP2D6, CYP3A4, and CYP1A2 [15].
The authors showed that the intake of a common user’s dose
of CAM could be confirmed in rat urine, with the hydroxy-
aryl CAM and the corresponding glucuronide metabolites
being the most abundant [15].
Thus, nowadays very little is known about the pharmacol-
ogy of Camfetamine but it may be expected to have similar
properties to its N-ethyl analogue Fencamfamine (FCF) [10].
However, Camfetamine is potentially less lipophilic (calcu-
lated log D (pH 7.4) = 0,01 whereas the value Fencamfamine
is 0,31) and this may result in lower bioavailability across
the blood brain barrier [10]. Fencamfamine (FCF) is a psy-
chostimulant that has complex effects in the central nervous
system. Regarding acute effects, some studies suggest that
FCF releases dopamine (DA) from both 𝛼-methyl-p-tyrosine
and reserpine pools at dopaminergic cerebral nerve terminals
[16]. FCF increased the homovanillic acid (HVA) levels in
nucleus accumbens, tuberculum olfactorium, and corpus
striatum and the dihydroxyphenylacetic acid (DOPAC) levels
in the nucleus accumbens; on the other hand, amphetamine
(AM) decreased the DOPAC levels in the 3 structures [16].
These data indicate that FCF and AM may differ from each
other on particular mechanisms by which catecholamines
are released [17]. In vitro, FCF blocked [3H] catecholamine
uptake into brain synaptosomes with potency similar to AM,
but the [3H] dopamine releasing activity in striatal slices
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Figure 1: Chemical characterization of N-methyl-3-phenyl-norbornan-2-amine, modified from [10].
was low compared to AM [17]. Thus, FCF seems to produce
its effects by predominant inhibition of DA reuptake, while
AM seems to act as a DA releaser [18]. These results were
confirmed bymicroiontophoretic approach [19]. FCF showed
low affinity for binding sites of DA receptors ligands and
little effect on wall brain monoamineoxidase activity [17, 20].
Considering all the evidences, we support the view that CAM,
as FCF, may act as an indirect dopaminergic agonist in the
central nervous system [21]. Moreover, interesting findings
suggest that uptake inhibition and the release properties
of FCF may undergo daily variation; the circadian time-
dependent effects of FCF might be related to a higher sus-
ceptibility of dopamine presynaptic terminals to the action
of FCF during the light phase which corresponds to the rats’
resting period [22].
Regarding long-term effects, it is well known that
repeated use of CNS stimulants can lead to either tolerance
or sensitization [23, 24]. Preclinical studies showed that the
behavioral effects of FCF include activation of locomotor, an
increase in the stereotyped sniffing, and paradoxical decrease
in rearing and behavior. At high doses, it induces stereotyped
behavior [16]. It was also shown that FCF can act as a pos-
itive reinforcer and was hypothesized that opioid receptors
mediate the reinforcing effects of FCF [25]. Furthermore,
changes in the sensitivity of pre- or postsynapticDA receptors
might underlie both tolerance and sensitization to the effects
induced by long-term FCF administration [26, 27]. Some
authors suggest that chronic FCF treatment is linked to
a modification in Na,K-ATPase activity through the cyclic
AMP-dependent protein kinase, nitric oxide synthase (NOS)
activity, and cyclic GMP levels in the nucleus accumbens
(NAc) and striatum (ST) [28].
Clinical data on Fencamfamine administration in healthy
volunteers showed that its stimulant effects are more pro-
nounced with higher dose (50mg), its paradoxically sedative
effects are obtained with lower dose (25mg), and it impairs
cognitive functioning, increases awakeness, and depresses
REM sleep [29]. To date, there is no human data that can
determine the chronic toxicity, the dependence, and abuse
liability of Camfetamine.
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Figure 2: Camfetamine and its N-ethyl analogue Fencamfamine are heterocyclic amphetamine derivatives. Modifying the aminoalkyl side
chain into heterocyclic structures still preserves the basic 𝛽-phenethylamine structure and retains the central stimulant activity without
marked anorexigenic and cardiovascular side effects.
3.2. Information on Camfetamine Availability and Consump-
tion. In general, the Internet seems to be an important source
to obtain NPS worldwide. The significant informational,
promotional, and distributional capacity of the Internet plays
an important role in the NPS market and global web-
based marketing and distribution distinct from illegal street
markets has developed in past years [30]. Our research has
identified 12 different websites in which customers can easily
buy Camfetamine online [31–42]. The Internet seems to offer
many advantages to NPS suppliers as it provides access to
a vast number of potential users and suppliers who do not
need large upfront investments and can retain some level
of anonymity. It is important to point out that, in many
cases, sellers fail to list ingredients hence raising further
concerns in terms of the presence of contaminating agents,
side effects, or drug interactions of the advertised product
[43, 44]. According to our searches, the first online reports on
Camfetamine use as recreational drug appeared in May 2011
both in Italy and UK with enthusiastic expectations among
users and potential users [45, 46]. Camfetamine is sold as
a white or brownish-yellow, clumpy, odourless, and salty
powder.The average prices are C11: 250mg; C20: 500mg; C38
per gram; C70: 2 g; C160: 5 g. It is most commonly sniffed or
taken by oral ingestion (frequent is the “bombing” technique,
e.g., wrappingCamfetamine in a cigarette paper and swallow-
ing it, or to melt it in drinks). Other ways of consumption
include smoking, intramuscular injection, intravenous, and
even rectal administration. Average doses range between 50
and 200mg. Furthermore, redosing appears to be a common
practice and typically involves the intake of more than one
dose of 50–100mg, with the total consumption up to 150–
250mg [11, 46–48].
Re: Camfetamine. An example of online report experience
with Camfetamine available online at http://www.psycho-
naut.com/sintetici/38797-camfetamine.html (accessed on
11/1/2014).
40 Year oldmale, 20+ years of experience withmost types
of illegal drugs, and a dozen or so different RC’s.
I received 500mg of the re-crystallized product from my
favourite, excellent vendor. It looks off-white with chunks and
clumps, no smell that I noticed, though I didin’t take it nasally
as it looked like it would be a painful experience.
+0 h: 80mg in a gelcap on an empty stomach, at the end of
a hard day at work shovelling concrete all day in the
sun, welp.
+1 h: Feeling slight stimulation, quite similar to Modafinil,
but with even less of a hard edge. Modafinil only
affects me at 400mg doses, but at that level it can be
slightly jittery, Camfetamine, so far, is more pleasant.
+2 h: Slightly more alert, mind seems to be working faster,
I catch up on a couple of zeropunctuation videos and
he sounds like he’s speaking slower than usual.
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+3 h: No euphoria, but I do feel good, especially consider-
ing the day I’ve had. I feel a bit hungry, but no real
desire to eat, though probably could if I wanted.
+3.5 h: Plateaux I think, so I take another 50mg.The reported
feeling of “smoothness” is definitely a good descrip-
tion. No jitteryness, no anxiety like I often get. Blood
pressure seems slightly raised, and occasionally think
I may have the beginnings of a headache, but it never
manifests. Pulse seems normal.
+4 h: Eat some food as my stomach is gurgling loudly. No
problems eating, rather nice actually.
+5 h: Probably the most “high” so far, wish I was going out
to a bar or the like, but just browse like a demon
instead. I watch some iPlayer, and it also seems slow,
this stuff might be a good study aid, or functional
stim. Definitely recreational too though imho.
+6 h: It’s 2 AM and normally Id be asleep after such a hard
(week) day at work, but I’m still wide awake and
feeling great.
+7 h: Been yawning for a bit now, though still very alert. I
have shit to do tomorrow so take 21mg Etizolam, go
to bed and sleep for 7 hours.
+13 h: Feel fine, a bit groggy from the benzo perhaps, and
slightly drained, perhaps because I would normal
sleep for 9 hours.
Summary. Nice stim, smooth and clean, a calming effect too,
as others have described. Not one for the true speed freaks,
but I enjoyed it and will try again with a 120 ish dose.
I was very dubious about the reported opioid effect, but
there may be some truth. I’m dpendant on dihydrocodeine
(again, ffs) I take 480mg in the morning and the same in the
evening. Last night after taking the camfetamine, I had no
desire for my DHC, felt none of the usual mild wd symptoms
either.
Not totally convinced, but it seems possible it does have
an opioid action. To know for sure, I’d have to take it, with no
opiates for 2-3 days. Heh, that’s not going to happen.
Not a great TR, the whole time I was on it I was trying
to think of good ways to describe how I feel, or something to
compare it to, but it is a weird one, not in a bad way, just not
quite like anything else I’ve tried.
I can’t imagine ever taking “real” speed again, too old, cant
be arsed with staying awake for days. Or psychosis. This feels
infinitely less toxic than the speed I’ve taken in the past, and
is a quite contradictory substance, mellow speed? Smooth,
calming, stimulation?
3.3. Desidered Effects and Side Effects. “Smooth” onset has
been frequently reported (see Re: Camfetamine). The effects
are described to reach the “high”within an hour and last for 4-
5 hours [45, 46, 48, 49]. Unlike other stimulants, many users
have reported the need to repeatedly redose this compound
in order to get any appreciable stimulant or recreational value
[46, 48, 50]. Desired effects include a marked improvement
in mental alertness, feeling of clarity, and a stimulant effect
followed by a sense of calmness and relaxation [45, 46, 48–
50] (see Re: Camfetamine). Some experiences report that
it also acts as a modest appetite suppressant and improves
fatigue. Users report mood changes ranging from no mood
enhancement to general pleasant mood or light euphoria
at higher doses [45, 46, 48, 50]. On the other hand, users
searching for strong euphoric/stimulant effects appear to be
critical and disappointed about Camfetamine reporting that
it is relatively ineffective and suggesting to choose other
stimulants or to use it in combination with other substances
[45–52].
Side effects manifested up to 24 hours after the intake
including anxiety, headache, depressed or disphoric mood,
unpleasant body sensations, and severe sleep impairment
[45, 46, 48]. However, some users do not report any side
effects. About adverse reactions, unlike “classic” stimulants
such as cocaine or amphetamine, Camfetamine seems
not to be commonly associated with severe physical
sympathomimetic effects such as hypertension or respiratory
difficulties [11]. Camfetamine is described by most of the
users to moderately increase heart/pulse rate, give a light
temperature increase, cause slight urinary retention, and
dilate pupils [46, 48]. All users report, after insufflation,
extremely unpleasant caustic burning sensations to nasal
mucous membrane tissue associated with runny nose,
squeezing, lacrimation, and corrosive feelings to the throat
[45, 46, 48, 50]. Higher doses do seem to increase the
stimulant effects of the drug but they also determine an
increase in the toxicity. Worrisome data issued in our
research are related to intramuscular or intravenous use
of Camfetamine that appear to be particularly toxic. It can
cause severe local pain in the site of puncture with marked
vasoconstriction, painful muscle tension and stiffness, ataxia,
blurred vision, muscle weakness, violent incontrollable
diffuse tremors, bruxism, and dystonia. For this reason,
some users do not recommend IV or IM administration
even after complex chemical processes of purification and
recrystallization [46, 48]. Within the sample considered
in our online monitoring, Camfetamine is commonly
taken in conjunction with many other psychoactive
substances such as alcohol, cannabis, cocaine, heroin,
amphetamine, Metamphetamine, MDMA as well as the less
common Methiopropamine (MPA), 5,6-methylenedioxy-
2-aminoindane (MDAI), methoxetamine (MXE), N,N-
dimethyltryptamine (DMT), 𝛼-pyrrolidinopropiophenone
(𝛼-PPP), 6-(2-aminopropyl)benzofuran (6-APB), Kanna,
Kratom, Dimethocaine, and Prolintane [45, 46, 48, 50]. This
polydrug use might be associated with a wide number of
unknown side effects/adverse reactions that are potentially
lethal. Like for other stimulants, Camfetamine is also
used in combination with various medications to self-treat
unpleasant effects due to its intake: sedative/hypnotics for
agitation and insomnia (Etizolam, Lorazepam, Temazepam,
and Clomethiazole), anticonvulsant/myorelaxants for
muscle tension and tremors (Pregabalin, Lamotrigine, and
Tizanidines), and antiemetic for nausea (Domperidone)
[45, 46, 48, 50]. Furthermore, many Camfetamine users
admit to be under current psychiatric treatment (e.g., with
antidepressants, mood stabilizers), without specifying the
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diagnosis, or under current opioid substitution/analgesic
therapy (Methadone, Buprenorphine, Naltrexone, Tramadol,
O-Desmethyltramadol, Codeine, Oxycodone, and Fentanyl)
and state to mix and misuse also other products (e.g., with
Methylphenidate and Modafinil) for recreational purposes
[45, 46, 48, 50].
4. Conclusions
The amphetamine-type stimulants class has always been
characterized by a large variety of substances. Among these,
Camfetamine represents just one of the latest trends within
the drug market. Starting from May 2011, N-methyl-3-
phenyl-norbornan-2-amine has been redeveloped for use as
a recreational drug. To the best of our knowledge, this is the
first paper providing both an overview of the current scien-
tific data available on Camfetamine and a critical analysis of
the information related to its psychoactive effects, side effects,
and use in combination with other drugs.
Camfetamine may act as an indirect dopaminergic ago-
nist in the central nervous system and may have mild-
moderate opioid activity too. It produces increased mental
alertness, relaxation and, unlike many other stimulants,
seems not to be associated with severe physical effects. Only
little is known in terms of risks; one could argue about
the possible risks associated with ingesting a drug that
presents with potential for dependence and the anecdotal
report on injecting use. A valid cause for concern issued
in our research may be its use in conjunction with other
psychoactive substances.
Nowadays, Camfetamine is largely available online and
thus “just a click” away from our homes and potentially
available to everyone. Moreover, the Internet serves as a
repository of information for several groups of people and
drug users can obtain information through online forums,
chat rooms, and blogs and find out about new products.
They can also communicate with other users on their expe-
riences, the effects of the substances, and the recommended
sources and avenues of delivery [53] (see Re: Camfetamine).
The apparent possibility to purchase Camfetamine from
Websites makes this drug very easily available to vulner-
able individuals, including children and adolescents [54].
Vulnerable individuals might be encouraged by a range of
widely available online comments/messages/videos related to
Camfetamine intake experiences. This may be an issue of
concern if one considers that an estimated 61% of young
European people aged between 15 and 24 years typically
quote the Internet as a potential source of information on
drugs [55]. Furthermore, Camfetamine seems to be mostly
unregulated and this may facilitate its popularity as well as
the users’ perception of risks associatedwith its consumption.
The idea that legality can equate with safety still remains well
grounded amongst some recreational users [56–60]. There
are no current epidemiological data about Camfetemine use
as recreational drug: our research shows that it exsists and
mostly in individuals with a history of recreational polydrug
misuse. Moreover, the fact that our research was carried out
using theGoogle search engine just in two languages (English
and Italian) might underestimate the Camfetamine diffusion.
A possible limitation of our analysis could be given by
the fact that publicly available websites, fora, and similar
sources were monitored. One could wonder about many
limitations of carrying out a risk of misuse assessment of
a drug while taking into account the online comments.
First, it may be inappropriate to trust information obtained
from the Internet without independent verification. Second,
the present findings do rely on what is reported by users
and we did not have any possibility here to ascertain if
the substance the online alleged drug users were taking
was indeed N-methyl-3-phenyl-norbornan-2-amine. Third,
Camfetamine effects/adverse reactions are described in our
qualitative analysis by a population of polyabusers as having
most probably a high tolerance to many substances, and
some of them declare even to be drug addicted or under
current psychiatric treatment. Globally, Camfetamine users
considered in our analysis, added together, are also intak-
ing alcohol, cannabis, cocaine, heroin, amphetamine and
synthetic amphetamine derivatives, Piperazine-based deriva-
tives, Mephedrone, Pipradrol and derivatives, aminoindane
analogues, Ketamine and derivatives, synthetic cannabinoid
receptor agonists, Tryptamines, Benzofurans and Benzodifu-
rans, natural product (Fungal andHerbal) novel psychoactive
substances, Benzodiazepines, Barbiturates, anticonvulsant,
antidepressants, and opioid substitution/analgesic therapies.
Such a phenomenon constitutes a serious public health chal-
lenge: pharmacological, toxicological, and psychopathologi-
cal effects due to interactions among all these substances may
be unpredictable and fatal in vulnerable individuals. More-
over, such a chronic polydrug intake may lead to neurobio-
chemical CNS alteration that might make these polyabusers
extremely difficult to be pharmacologically treated even
by expert mental health professionals. On the other hand,
online reports about the experience with Camfetamine seem
genuine and many users illustrate their detailed experiences
with Camfetamine as proper experiments (see Re: Cam-
fetamine). Thus, in the absence of relevant peer-reviewed
data, the online monitoring seems to be indeed the only
method to obtain preliminary information about new and
emergent phenomena. One could conclude that a constant
web-monitoring activity with respect to drug-related issues
is necessary to better understand the level of the diffusion
of novel psychoactive substances such as Camfetamine.
It is here suggested that better international collaboration
levels may be needed to tackle the novel and fast growing
phenomenon of novel psychoactive drugs availability from
the web. Furthermore, it is here highlighted that more large-
scale studies need to be carried out to confirm and better
describe the extent as well as the risks of Camfetamine use in
the European Union and elsewhere. Again, health and other
professionals should be rapidly informed about this and other
new and alerting trends of misuse. In this context, we suggest
that the use of technological tools could be successfully
incorporated in specific prevention programmes targeted
at both health professionals and young people looking for
reliable information about novel psychoactive substances.
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